Clinical Value of CXCL5 for Determining of Colorectal Cancer

Abstract

Background: Several studies indicate that chemokines play important roles in colorectal mucosal immunity.<br />The chemokine CXCL5 which is expressed by epithelial cells within colorectal mucosa is a promoter of cell proliferation,<br />migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. The purpose of this study<br />was to investigate whether serum and tissue CXCL5 levels is altered in colorectal carcinomas (CRC) compared to colonic<br />adenoma and normal mucosa.It also aimed to compare colon adenoma and colorectal cancer for blood CXCL5 and<br />CEA levels, their sensitivity, and specificity. Methods: CXCL5 expression was assessed with immunohistochemistry<br />staining in biopsy samples taken during colonoscopy in 22 colonic adenomas, 23 colorectal carcinomas and 23 normal<br />colonic tissue samples. Also all patients' serum CXCL5 and CEA levels were measured. This stduy was prospective<br />observational study. Results: The number of cases who were stained positive with immunohistochemistry was found to<br />be higher in the group with CRC. When compared with the other groups, both levels of serum CXCL5 and CEA were<br />significantly high in the group CRC. Sensitivity and specificity of serum CXCL5 were found to be low as a result of<br />the ROC analysis. Conclusion: Although the level of CXCL5 is high in CRC, its level in serum is not significant<br />enough to support the early diagnosis of the disease.